Shine-On BioMedical Co (ROCO:6926) Other Current Liabilities: NT$0.20 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6926 Shine-On BioMedical Co Ltd ROCO:6926
13 GF Score
Price NT$63.00
View Full Analysis

What is Shine-On BioMedical Co Other Current Liabilities?

Shine-On BioMedical Co ROCO:6926 +0.16% 13 Other Current Liabilities is NT$0.20 Mil as of Dec. 2025. GuruFocus rates ROCO:6926 with a GF Score™ of 13/100.

Shine-On BioMedical Co's other current liabilities for the quarter that ended in Dec. 2025 was NT$0.20 Mil.

Shine-On BioMedical Co's quarterly other current liabilities declined from Dec. 2024 (NT$0.21 Mil) to Jun. 2025 (NT$0.11 Mil) but then increased from Jun. 2025 (NT$0.11 Mil) to Dec. 2025 (NT$0.20 Mil).

Shine-On BioMedical Co's annual other current liabilities increased from Dec. 2023 (NT$0.18 Mil) to Dec. 2024 (NT$0.21 Mil) but then declined from Dec. 2024 (NT$0.21 Mil) to Dec. 2025 (NT$0.20 Mil).

Shine-On BioMedical Co Other Current Liabilities Related Terms

Shine-On BioMedical Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Shine-On BioMedical Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shine-On BioMedical Co Other Current Liabilities Chart

Shine-On BioMedical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 0.03 0.08 0.18 0.21 0.20

Shine-On BioMedical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.08 0.21 0.11 0.20
ROCO:6926
13GF Score
Shine-On BioMedical Co Ltd ROCO:6926
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shine-On BioMedical Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of NT$0.20 Mil mean?
Shine-On BioMedical Co (ROCO:6926) has a Other Current Liabilities of NT$0.20 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shine-On BioMedical Co.
Is Shine-On BioMedical Co's Other Current Liabilities too high?
Shine-On BioMedical Co's current Other Current Liabilities is NT$0.20 Mil. Overall, Shine-On BioMedical Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Shine-On BioMedical Co's Other Current Liabilities compare to VRTX and REGN?
Shine-On BioMedical Co's Other Current Liabilities of NT$0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shine-On BioMedical Co. Shine-On BioMedical Co's current Other Current Liabilities is NT$0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shine-On BioMedical Co stock overvalued right now?
Shine-On BioMedical Co (ROCO:6926) has a current Other Current Liabilities of NT$0.20 Mil. The current Other Current Liabilities is NT$0.20 Mil. Shine-On BioMedical Co's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Shine-On BioMedical Co (ROCO:6926), the current Other Current Liabilities is NT$0.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shine-On BioMedical Co Business Description

Address No. 573, Taiwan Boulevard, 10th Floor, Section 2, West District, Taichung, TWN
Shine-On BioMedical Co Ltd develops drugs based on antibodies and nucleic acids. The Company researches, develops, manufactures, and distributes antibody anticancer drugs, nucleic acid anticancer drugs. The company's drug development and nucleic acid therapeutics are focused on providing patients with effective cancer treatment options.
13GF Score

Get the complete analysis for ROCO:6926

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.00
Price